ARTICLE | Company News
Tango, Gilead partner to discover immune evasion cancer targets
November 2, 2018 7:53 PM UTC
Tango Therapeutics Inc. (Cambridge, Mass.) and Gilead Sciences Inc. (NASDAQ:GILD) will employ Tango's functional genome-based platform to discover tumor-intrinsic immune evasion targets. Gilead will have worldwide options to five targets under the deal.
Tango will receive $50 million up front and be eligible to receive about $1.7 billion in preclinical fees and milestones, plus low double-digit tiered royalties...